Important Information for Investors of ESSA Pharma Inc.: Rosen Law Firm Reminds of Class Action Lawsuit and Lead Plaintiff Deadline
Rosen Law Firm, a global investor rights law firm, is reminding purchasers of securities of ESSA Pharma Inc. (NASDAQ: EPIX) between December 12, 2023, and October 31, 2024, inclusive (the “Class Period”), of the significant deadline in a securities class action lawsuit. This deadline, known as the lead plaintiff deadline, is March 25, 2025.
What is a Securities Class Action Lawsuit?
A securities class action lawsuit is a legal action brought on behalf of a large group of investors who have suffered losses due to alleged violations of securities laws. In this case, the lawsuit alleges that ESSA Pharma and certain of its top executives made false and misleading statements to the market, which artificially inflated the company’s stock price.
Who is Affected?
If you purchased ESSA Pharma securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The compensation could potentially include damages for financial losses.
How Will This Affect Me?
If you meet the criteria mentioned above, you have the opportunity to join the class action lawsuit as a lead plaintiff. As a lead plaintiff, you would help shape the direction of the lawsuit and potentially receive a larger share of any recovered damages.
How Will This Affect the World?
The outcome of this case could have significant implications for the biotech industry and the investment community at large. It could serve as a reminder to companies to ensure the accuracy of their public disclosures and to investors to carefully consider the potential risks and rewards of their investment decisions.
Lead Plaintiff Deadline: March 25, 2025
The lead plaintiff deadline is a critical date for investors. If you wish to seek appointment as lead plaintiff, you must act before this deadline. Failure to do so may result in your right to share in any future recovery being waived.
Contact Information
If you purchased ESSA Pharma securities during the Class Period and wish to join the action as a lead plaintiff, please contact Laurence Rosen, Esq. or Deena Manzagol, Esq. of Rosen Law Firm, toll-free at 866-767-3653 or via email at [email protected] or [email protected] for information on the class action.
Additional Information
For more information about the lawsuit, please visit
About Rosen Law Firm: Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. The firm was Ranked No. 1 in the number of securities class action settlements in 2019 and 2020.
Disclaimer
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Rosen Law Firm is not admitted to practice law in all jurisdictions where provisions of this press release are released, and certain attorneys in the firm are primarily responsible for the supervision, management, and rendering of legal services in specific matters. Prior results do not guarantee a similar outcome.
- Rosen Law Firm
- Global investor rights law firm
- Lead plaintiff deadline: March 25, 2025
- ESSA Pharma securities purchased during Class Period
- Potential compensation for financial losses
- Opportunity to join as lead plaintiff
- Potential implications for biotech industry and investment community
- Contact Rosen Law Firm for more information
Conclusion
Investors who purchased ESSA Pharma securities between December 12, 2023, and October 31, 2024, have until March 25, 2025, to seek appointment as lead plaintiff in a securities class action lawsuit against the company. If you meet the criteria mentioned above, you could potentially be entitled to compensation for any financial losses you suffered. This case could have significant implications for the biotech industry and the investment community at large, serving as a reminder to companies to ensure the accuracy of their public disclosures and to investors to carefully consider the potential risks and rewards of their investment decisions. For more information, contact Rosen Law Firm.
